

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitution for form 1449A/PTO INFORMAL DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known Application Number 10/593,578 Filing Date September 20, 2006 First Named Inventor GEWIRTZ, Alan M. Art Unit Not yet known Examiner Name Not yet known Attorney Docket Number P-7782-US	
Sheet	1	of	3		

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	/Sean McGarry/	Date Considered	07/29/2009
-----------------------	----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). ¹ See Kinds Codes of USPTO Patent Documents at www.uspto.gov and MPEP 801.04. ² Enter Office that issued the document, by the two letter code (WIPO Standard 3.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST 16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. The collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending on the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /SM/

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Application Number	10/593,578
				Filing Date	September 20, 2006
				First Named Inventor	GEWIRTZ, Alan M.
				Art Unit	Not yet known
				Examiner Name	Not yet known
Sheet	2	of	3	Attorney Docket Number	P-7782-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C	ARTIGA MJ et al. "A short mutational hot spot in the first intron of BCL-6 is associated with increased BCL-6 expression and with longer overall survival in large B-cell lymphomas." Am J Pathol. 2002 Apr;160(4):1371-80.	
	D	BARON BW et al. "Identification of the gene associated with the recurring chromosomal translocations t(3;14)(q27;q32) and t(3;22)(q27;q11) in B-cell lymphomas." Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):5262-6.	
	E	BARRANS SL et al. "Rearrangement of the BCL6 locus at 3q27 is an independent poor prognostic factor in nodal diffuse large B-cell lymphoma." Br J Haematol. 2002 May;117(2):322-32.	
	F	BRAATEN KM et al. "BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma." Clin Cancer Res. 2003 Mar;9(3):1063-9.	
	G	BRINDLE KM, Br. J. Radiol. 78 Spec., No. 2:S111-7, 2003	
	H	BUCHWALD et al., Surgery 88:507, 1980	
	I	CAUDY AA et al., Gene & Devel, 16:2491-96	
	J	CHANG CC et al. "BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor" PNAS 93(14): 6947-52, 1996	
	K	CHANG CC et al. "Expression of p53, c-Myc, or Bcl-6 suggests a poor prognosis in primary central nervous system diffuse large B-cell lymphoma among immunocompetent individuals." Arch Pathol Lab Med. 2003 Feb;127(2):208-12.	
	L	GOODSON, Medical Applications of Controlled Release, Supra, vol. 2, pp. 115-138, 1984	
	M	GIFFORD et al. "Identification of antisense nucleic acid hybridization sites in mRNA molecules with self-quenching, fluorescent reporter molecules", Nucleic Acids Research, 2005, vol. 33, No. 3, 9 Pages	
	N	HARRIS NL et al "A revised European-American classification of lymphoid neoplasms. a proposal from the International Lymphoma Study Group." Blood. 1994 Sep 1;84(5):1361-92.	
	O	JERKEMAN M et al. "Prognostic implications of BCL6 rearrangement in uniformly treated patients with diffuse large B-cell lymphoma—a Nordic Lymphoma Group study." Int J Oncol. 2002 Jan;20(1):161-5.	
	P	KAWASAKI C et al. "Rearrangements of bcl-1, bcl-2, bcl-6, and c-myc in diffuse large B-cell lymphomas." Leuk Lymphoma. 2001 Sep-Oct;42(5):1099-106.	
	Q	LOSSOS IS et al. "Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma." Blood. 2001 Aug 15;98(4):945-51.	
	R	LAHORTE CM et al., Eur. J. Nucl. Med. Mol. Imaging 31(6):987-919 2004	

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Application Number	10/593,578
		Filing Date	September 20, 2006
		First Named Inventor	GEWIRTZ, Alan M.
		Art Unit	Not yet known
		Examiner Name	Not yet known
(use as many sheets as necessary)			
Sheet	3	of	3
		Attorney Docket Number	P-7782-US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (where appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	S	LANGER, Science, 249:1527-1533, 1990	
	T	KALOTA A, "Design of antisense oligonucleotides and short interfering RNA duplexes (siRNA) targeted to BCL6 mRNA: towards rational drug development for specific lymphoma subsets". JB. Blood Cells Mol Dis. 2007 May-Jun;38(3):199-203. Epub 2007 Jan 24.	
	U	OPALINSKA et al., "Oxetance modified, Conformationally Constrained, antisense Oligodeoxynucleotides function efficiently as gene silencing molecules", Nucleic Acids Research, 2004, vol. 32, No. 19, 5791-5799	
	V	SÁNCHEZ-BEATO M et al. "Cell cycle deregulation in B-cell lymphomas." Blood. 2003 Feb 15;101(4):1220-35. Epub 2002 Sep 12.	
	W	SAUDEK et al., N. Engl. J. Med. 321:574, 1989	
	X	SEFTON, CRC Crit. Ref. Biomed. Eng. 14:201, 1987	
	Y	SHAFFER AL et al. "BCL-6 represses genes that function in lymphocyte differentiation, inflammation, and cell cycle control." Immunity. 2000 Aug;13(2):199-212.	
	Z	SOKOL et al., "Real time detection of DNA-RNA hybridization in Living Cells", Proc. Natl. Acad. Sci. USA, vol. 95, pp. 11538-11543, September 1998	
	AA	TANG TT et al. "The forkhead transcription factor AFX activates apoptosis by induction of the BCL-6 transcriptional repressor." J Biol Chem. 2002 Apr 19;277(16):14255-65. Epub 2002 Jan 2.	
	AB	UEDA C et al. "Non-immunoglobulin/BCL6 gene fusion in diffuse large B-cell lymphoma: prognostic implications." Leuk Lymphoma. 2002 Jul;43(7):1375-81.	
	AC	VITOLO U et al. "Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma." Leukemia. 2002 Feb;16(2):268-75.	
	AD	YE BH et al. "Chromosomal translocations cause deregulated BCL6 expression by promoter substitution in B cell lymphoma." EMBO J. 1995 Dec 15;14(24):6209-17.	
	AE	YE BH et al. "The BCL-6 proto-oncogene controls germinal-centre formation and Th2-type inflammation." Nat Genet. 1997 Jun;16(2):161-70.	
	AF	International Search Report of Application No. PCT/US05/09349 dated August 16, 2006	

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

The collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.